Clinical Scorecard: Risk Assessment Based on Folate Metabolism Reveals CYP27B1 as a Key Factor in Tumor Advancement in Head and Neck Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Head and Neck Squamous Cell Carcinoma (HNSCC)
Key Mechanisms
Folate metabolism and its association with tumorigenesis, immune response, and chemoresistance.
Target Population
Patients with HNSCC
Care Setting
Oncology
Key Highlights
FMRG_score serves as an independent prognostic indicator for HNSCC.
High FMRG_score correlates with poor survival and chemoresistance.
CYP27B1 knockdown enhances cisplatin sensitivity in HNSCC.
Immune deconvolution shows reduced anti-tumor immune infiltration in high-risk tumors.
Nomogram combining FMRG_score and clinical parameters shows strong predictive performance.
Guideline-Based Recommendations
Diagnosis
Utilize FMRG_score for risk stratification in HNSCC patients.
Management
Consider CYP27B1 as a therapeutic target to improve treatment outcomes.
Monitoring & Follow-up
Regularly assess FMRG_score to evaluate tumor progression and treatment response.
Risks
High FMRG_score indicates increased risk of poor prognosis and chemoresistance.
Patient & Prescribing Data
Patients diagnosed with HNSCC, particularly those at high risk based on FMRG_score.
Cisplatin sensitivity may be improved through CYP27B1 modulation.
Clinical Best Practices
Incorporate FMRG_score in clinical decision-making for HNSCC.
Monitor immune profiles alongside metabolic markers in HNSCC management.
